このページの翻訳は実験的なもので、現在開発中です。お待ちしております

MAIA Biotechnology マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Vlad Vitoc

最高経営責任者

US$1.4m

報酬総額

CEO給与比率	33.1%
CEO在任期間	no data
CEOの所有権	4.3%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	3yrs

経営陣の近況

Recent updates

CEO報酬分析

MAIA Biotechnology の収益と比較して、Vlad Vitoc の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$28m
Mar 31 2024	n/a	n/a	-US$24m
Dec 31 2023	US$1m	US$473k	-US$20m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$1m	US$443k	-US$16m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$703k	US$265k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Dec 31 2020	US$1m	US$75k	-US$7m

報酬と市場: Vladの総報酬 ($USD 1.43M ) は、 US市場 ($USD 667.63K ) の同規模の企業の平均を上回っています。

報酬と収益: Vladの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Vlad Vitoc (54 yo)

no data

在職期間

US$1,430,757

報酬

Dr. Vlad Vitoc, MD., MBA., is the Co-founder, Chairman, President and Chief Executive Officer of MAIA Biotechnology, Inc. Dr. Vitoc is a well-seasoned biotech executive with a broad array of experience acr...

取締役

名称	ポジション	在職期間	報酬	所有権
Vlad Vitoc	Co-Founder	no data	US$1.43m	4.26% $ 2.7m
Ngar Louie	Independent Director	4.4yrs	US$90.00k	4.88% $ 3.0m
Jerry Shay	Chairman of Scientific Advisory Board	3yrs	データなし	データなし
Steven Chaouki	Independent Director	3yrs	US$60.00k	0.37% $ 232.0k
Ramiro Guerrero	Independent Director	no data	US$60.00k	1.34% $ 834.2k
Cristian Luput	Independent Director	no data	US$60.00k	1.54% $ 958.8k
Stan Smith	Lead Independent Director	no data	US$75.00k	4.2% $ 2.6m
David Ashley	Member of Scientific Advisory Board	3yrs	データなし	データなし
Tudor Ciuleanu	Member of Scientific Advisory Board	3yrs	データなし	データなし
Z. Dikmen	Member of Scientific Advisory Board	3yrs	データなし	データなし
Adam Yopp	Member of Scientific Advisory Board	3yrs	データなし	データなし
Jean-Manasse Theagene	Independent Director	1.5yrs	US$47.50k	0% $ 0

3.0yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: MAIAの取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

MAIA Biotechnology マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

Lead Independent Director recently bought US$300k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference

New major risk - Financial position

Maia Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent

Maia Biotechnology Reveals New Clinical Data Showing Thio’s Strong Efficacy in Non-Small Cell Lung Cancer

New major risk - Share price stability

MAIA Biotechnology, Inc. announced a financing transaction

MAIA Biotechnology, Inc. announced that it expects to receive $0.664994 million in funding

MAIA Biotechnology, Inc., Annual General Meeting, May 24, 2024

MAIA Biotechnology, Inc. announced that it expects to receive $1.327985 million in funding

MAIA Biotechnology, Inc. Appoints Saadettin Kilickap to its Scientific Advisory Board

MAIA Biotechnology, Inc. Announces Positive Efficacy Data for Third-Line Treatment in its Phase 2 THIO-101 Clinical Trial Evaluating THIO Sequenced with CPI Cemiplimab in Advanced NSCLC

MAIA Biotechnology, Inc. Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. has filed a Follow-on Equity Offering in the amount of $1.445 million.

MAIA Biotechnology, Inc. Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer

Maia Biotechnology, Inc. Announces Publication of International Pct Patent Application Covering Anticancer Telomere-Targeting Compounds

MAIA Biotechnology, Inc. Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024

MAIA Biotechnology, Inc. Announces Dose Selection in Thio-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

NYSE American Believes MAIA Biotechnology Not in Compliance with Listing Standards

MAIA Biotechnology, Inc. Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

MAIA Biotechnology, Inc. Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

MAIA Biotechnology, Inc. Announces Potent Anticancer Activity of THIO in Gliomas

MAIA Biotechnology, Inc. Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. (NYSEAM:MAIA) announces an Equity Buyback for $0.8 million worth of its shares.

New major risk - Revenue and earnings growth

MAIA Biotechnology, Inc. Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Reports Updates on Preliminary Survival Data for Thio-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Files Second Patent for New Telomere-Targeting Molecules Program

Lead Independent Director recently bought US$300k worth of stock

MAIA Biotechnology, Inc. Announces it Intends to Initiate its Second Phase 2 Go-To-Market Trial Evaluating THIO

MAIA Biotechnology, Inc. Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc. Expands Phase 2 THIO-101 Trial to Europe

High number of new and inexperienced directors

MAIA Biotechnology, Inc. has completed an IPO in the amount of $10 million.

High number of new and inexperienced directors

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14